2020
DOI: 10.1016/j.therap.2020.05.007
|View full text |Cite
|
Sign up to set email alerts
|

Prolonged-release buprenorphine formulations: Perspectives for clinical practice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
14
0
2

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
2
1

Relationship

2
7

Authors

Journals

citations
Cited by 28 publications
(20 citation statements)
references
References 27 publications
1
14
0
2
Order By: Relevance
“…Further, the consumption of large amounts of potent street benzodiazepines, a particularly worrying issue among PWUD in Scotland, reduces the threshold of the ceiling effect of buprenorphine, removing the protection patients normally have against respiratory depression ( Independent Expert Working Group, 2017 ). Once administered, the depot injection dose cannot be removed and the long duration of action of buprenorphine magnified by its prolonged release formulation will limit the effectiveness of naloxone ( Chappuy et al, 2020 ). Unfortunately, the extent to which this scenario is likely to increase patient risk is as yet poorly understood.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Further, the consumption of large amounts of potent street benzodiazepines, a particularly worrying issue among PWUD in Scotland, reduces the threshold of the ceiling effect of buprenorphine, removing the protection patients normally have against respiratory depression ( Independent Expert Working Group, 2017 ). Once administered, the depot injection dose cannot be removed and the long duration of action of buprenorphine magnified by its prolonged release formulation will limit the effectiveness of naloxone ( Chappuy et al, 2020 ). Unfortunately, the extent to which this scenario is likely to increase patient risk is as yet poorly understood.…”
Section: Discussionmentioning
confidence: 99%
“…The projected benefits of depot buprenorphine included increased protection of frontline workers and patients seeking MAT from droplet spread of COVID-19 by reducing daily or frequent attendances in pharmacies, enabling people who have been asked by the government to self-isolate or shield to be able to do so, reducing the impact upon patients of pharmacies being closed due to illness or quarantine ( Chappuy et al, 2020 ; Straub et al, 2020 ). Further, depot buprenorphine also negates the risks such as diversion or overdose implicit in allowing larger amounts of takeaway controlled drugs to minimize unnecessary travel, and the efficacy of treatment will no longer be dependent on the patients adherence to daily dosing, resulting in less risk of overdose and withdrawals ( Vorspan et al, 2019 ; Chappuy et al, 2020 ).…”
Section: Introductionmentioning
confidence: 99%
“…En ambos casos la duración de la liberación de buprenorfina a partir del sistema es de 1 mes (90). Su-blocade®, a diferencia de otros sistemas, debe conservarse en refrigeración (2-8 ºC) debido a que su estabilidad no supera los 7 días a temperatura ambiente (87). difusión de naltrexona a través del polímero, esta difusión proporciona una liberación sostenida de la naltrexona durante 30 días; esta rapidez en la instauración de la liberación permite que no haya que acudir a la suplementación oral de naltrexona en las etapas iniciales.…”
Section: Sublocade®unclassified
“…4 For all these reasons, new formulations of extendedrelease buprenorphine (XR-BUP) have recently been developed and commercialized, offering a one-week, onemonth, or six-month treatment coverage to OUD subjects, through subcutaneous depot or implant formulations. 5 Two depot forms, ie Buvidal ® (Camurus ® , Sweden) and Sublocade ® (Indivior ® , USA), have been approved in different countries. Furthermore, an implant, Sixmo ® , has been approved in the USA and in Europe.…”
Section: Introductionmentioning
confidence: 99%